Filing Flows › Aquestive Therapeutics (AQST) › Q3 2026 › vs Q3 2025
Aquestive Therapeutics (AQST) Q3 2026 vs Q3 2025 (year over year)
Aquestive Therapeutics's revenue fell $5.2M (-41%) from $12.8M in Q3 2025 to $7.6M in Q3 2026. The biggest changes: Manufacture and supply revenue −$4.8M (-42%); Co-development and research fees −$228K (-75%); License and Royalty Revenue −$214K (-21%).
Aquestive Therapeutics, Q3 2026: revenue $7.6M (-41% year over year), operating margin -191.5%, net loss $16.5M, operating cash flow −$7.0M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Manufacture and supply revenue | $6.7M | $11.5M | −$4.8M | -42% |
| License and Royalty Revenue | $824K | $1.0M | −$214K | -21% |
| Co-development and research fees | $74K | $302K | −$228K | -75% |
| Revenue | $7.6M | $12.8M | −$5.2M | -41% |
| Net loss | $16.5M | $15.4M | $1.1M | +7% |
| Costs & expenses | $24.1M | $28.3M | −$4.2M | -15% |
| Operating costs | $22.0M | $24.3M | −$2.3M | -9% |
| Interest & other, net | $2.0M | $4.0M | −$1.9M | -49% |
| Cost of revenue | $3.6M | $4.5M | −$900K | -20% |
| Research & development | $4.3M | $4.5M | −$279K | -6% |
| SG&A | $14.2M | $15.2M | −$1.1M | -7% |
| Operating cash sources | $16.5M | $15.4M | $1.1M | +7% |
| Depreciation | $156K | $139K | $17K | +12% |
| Share-based compensation | $2.1M | $2.8M | −$651K | -23% |
| Working capital & other | $7.2M | −$119K | $7.3M | — |
| Cash used in operations | $7.0M | $12.6M | −$5.6M | -44% |
| Net loss absorbed | $16.5M | $15.4M | $1.1M | +7% |
Questions
How much did Aquestive Therapeutics's revenue grow year over year in Q3 2026?
Aquestive Therapeutics's revenue fell $5.2M (-41%) from $12.8M in Q3 2025 to $7.6M in Q3 2026.
What drove Aquestive Therapeutics's revenue change in Q3 2026?
Manufacture and supply revenue −$4.8M (-42%); Co-development and research fees −$228K (-75%); License and Royalty Revenue −$214K (-21%).